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In this issue of Liver Transplantation, Donckier et al. 1 
report on 3 patients with primary hepatic malignancies 
who underwent live donor liver transplantation. fol-
lowed 1 week later by an infusion of fractionated stem 
cells obtained from the blood of the granulocyte colony-
stimulating factor (G-CSF)-conditioned donor. The in-
tention of the Brussels team was to limit immunosup-
pression to the first few postoperative weeks by 
promptly establishing donor leukocyte chimerism-as-
sociated tolerance. In cases 1 and 2. immunosuppres-
sion was discontinued as planned, about 3 weeks post-
operatively. Approximately 3 months later, mild acute 
rejections occurred that were reversed with a short 
course of immunosuppression. Treatment was then 
successfully stopped, with subsequent in vitro evidence 
of donor specific nonreactivity. These 2 patients were 
immunosuppression free for >95% of the time between 
liver replacement and death from recurrent malignancy 
at 561 and 356 days. For patient 3, immunosuppres-
sion discontinuance was put off until 213 days because 
of a surgical complication. When a reversible rejection 
developed. no further effort was made to stop treat-
ment. This patient is currently on small daily doses of 
tacrolimus and is tumor free at 498 days. 
As the authors emphasized, these results were in-
compatible with the immunologic paradigm upon 
which the strategy was based. The paradigm evolved 
historically in the following way. After the demonstra-
tion in 1953 that acquired allotolerance is strongly as-
sociated with donor leukocyte chimerism,2 attempts 
were made in the 1950s to produce chimerism in cytoa-
blated organ recipients by infusing donor leukocytes 
before or at the time of organ transplantation. 3 .4 Such 
efforts failed, because the donor cells either caused 
lethal graft versus host disease (GVHD) or were re-
jected. When human kidney transplantation was ac-
complished in the early 1960s under continuous drug 
immunosuppression without cytoablation/reduction 
or leukocyte infusion, it was widely concluded that leu-
kocyte chimerism played no role in the induction or the 
perpetuation of organ alloengraftment. 5 With this as-
sumption, experimental efforts were renewed to give 
organ reCipients the tolerance advantages of leukocyte 
chimerism while avoiding GVHD. This proved to be pos-
sible in selected cytoablation and cytoreduction mod-
els.6 - B but only when donor cells made up 2: 1 % of the 
recipient blood leukocytes (macrochimerism).9 Lower 
levels (micro chimerism) had no effect. When these mod-
el-specific observations were generalized, the sharp dis-
tinction between macro chimerism and microchimerism 
became dogma. 10-13 In addition, the dogma that organ 
engraftment occurs by mechanisms different from bone 
marrow transplantation appeared to be strengthened. 
The foregoing dogmas, as well as the overarching 
immunologic paradigm that had been distorted by the 
incorporation of those dogmas, were challenged in 
1991-92, when multilineage donor leukocyte microchi-
merism was detected in all long-surviving human organ 
recipients. 14.15 It was evident that migration of an or-
gan's passenger leukocytes (including stem cells) into 
the reCipient had been the previously unrecognized 
equivalent of a bone marrow cell infusion. The picture 
was made complete by the demonstration of "reversed 
proportion" mixed chimerism (i.e .. small numbers of 
persisting host leukocytes) in essentially all bone mar-
row recipients previously thought to have total hema-
tolymphopoietic cell replacement. 16 These findings uni-
fied the immunology of the 2 kinds of transplantation. 1 7 
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Moreover, only 2 mechanisms involving the mobile 
leukocytes were needed to explain how an allograft 
could avoid rejection. 18 One mechanism was immune 
ignorance: i.e., failure of the immune system to recog-
nize the presence of donor leukocytes that failed to 
reach host lymphoid organs. 18-20 The other mechanism 
(and the seminal one of acquired tolerance) was ex-
haustion-deletion of the clonal T-cell response induced 
by cells that reached the lymphoid sites. 14. 15. 18 The 
paradigm shift mandated by the micro chimerism and 
related discoveries was facilitated by formal proof of the 
existence and importance of both immune ignorance20 
and exhaustion-deletion,21.22 and ultimately by formal 
proof that leukocyte chimerism, even at a micro level. is 
essential for perpetuation of clonal exhaustion-deletion 
and tolerance. 23 
In the new paradigm, 18 it was proposed that all out-
comes after transplantation are determined by the bal-
ance established between the amount of mobile donor 
antigen (donor leukocytes) with access to host lym-
phoid organs and the number of donor-specific cytolytic 
T cells (CTL) induced at the lymphoid sites (Fig. lA). In 
this view, it is axiomatic that the prolonged engraftment 
of an organ, with or without the aid of maintenance 
immunosuppression, connotes some degree of partial 
donor leukocyte chimerism-dependent tolerance. In 
some cases, very small numbers of donor leukocytes 
may be sufficient to retain ascendancy over donor-re-
active CTL. Even if the CTL arm gains supremacy, im-
munosuppression can restore and maintain a favorable 
balance as depicted in Figure lA. This is the usual 
outcome after clinical organ transplantation. 14. 15. 17. 18 
It follows that the completeness of tolerance short of 
the drug-free state can be inferred from the amount of 
immunosuppression needed to maintain graft stabili-
ty.18.24.25 None of the patients of Donckier et al. 1 had 
macrochimerism. But the first 2 recipients clearly 
achieved a high degree of drug-free tolerance that can 
be considered with certainty to be microchimerism de-
pendent. 23.26.27 Moreover, their third patient was in no 
sense a tolerance-induction failure. Although the bal-
ance between mobile donor antigen (micro chimerism) 
and antigen-reactive T cells was close to the null point 
shown in Figure lA (the lower dotted lines). the small 
amount of daily tacrolimus needed to maintain a stable 
equilibrium in this patient reflected partial tolerance in 
spite of the in vitro evidence of ongOing antidonor reac-
tivity. 
The concept that balances between mobile antigen 
and antigen-specific T cells govern immunologic re-
sponsiveness and nonresponsiveness 18 has profound 
therapeutic implications. 25 Ratcheting down the re-
sponse arm with immunosuppression as shown in Fig-
ure lA has been the usual means of perpetuating organ 
alloengraftment. but at the costly loss ofT-cell surveil-
lance of malignant neoplasms and infections. The less 
damaging possibility of tilting the balance by simply 
giving organ recipients adjunct donor leukocyte infu-
sions has been shown empirically to improve allograft 
survival in numerous experimental transplant models. 
However, large-scale trials of adjunct leukocyte infu-
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Figure 1. The balance of mobile donor antigen (passenger 
leukocytes) and donor-reactive T cells that determines de-
structive immunity (rejection) or nonreactivity (variable toler-
ance) after organ transplantation. (A) If the quantity of self-
renewing leukocytes retain dominance over the antigen. 
specific cytolytic T lymphocytes. the T cell response may be 
exhausted and deleted. This is most likely to result in a drug-
free state if there is a large quantity of persistent donor cells 
(macrochimerism). but variable drug-free stable balances may 
be reached with microchimerism. Alternatively. a balance in 
which the T-cell response dominates can be tilted in favor of 
the leukocytes with immunosuppression. This is the usual 
scenario of organ transplantation under conventional immu-
nosuppression. and it is epitomized by the third patient of 
Donckier et aI. (8) The outcome in liver recipients 1 and 2 
reported by Donckier et aI. The solid line denotes donor anti· 
gen (leukocytes). The upright dotted line denotes the host 
versus graft response. The inverted dashed line denotes a 
larger graft versus host reaction than that seen in (A). 
sion have yielded disappointing results in human organ 
transplant recipients. 28-3o In these clinical trials, the 
infusion of bone marrow cells, or stern-cell-enriched 
peripheral leukocytes, usually was given on the same 
day as organ transplantation under conventional mul-
tiple-drug immunosuppression. What was the reason 
for the lack of efficacy? 
In 200 I, it was suggested thai heavy posttransplant 
immunosuppression systematically narrowed the win-
dow of opportunity for initial clonal exhaustion-deletion 
that coincides with the sudden passenger leukocyte 
migration.25 Such heavy treatment also would be ex-
pected to abrogate the potential benefit of additional 
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infused cells. When over-immunosuppression is later 
reduced, recovery of the inefficiently deleted clone 
would leave the patient prone to chronic rejection and 
dependent on lifetime drug treatment. On the other 
hand, failure to give enough early immunosuppression 
would lead to irreversible damage to the transplanted 
organ. It was proposed that the dilemma of over- vs. 
under-immunosuppression' in the organ recipient 
(without or with adjunct leukocytes) could be ad-
dressed by applying 2 therapeutic principles. singly or 
together: recipient pretreatment and minimal post-
transplant immunosuppression.25 These principles 
have been applied in Pittsburgh since 2001 with en-
couraging results in liver and other organ recipi-
ents.31-34 
The same principles can be readily identified in the 
strategy reported by Donckier et a1. Immunosuppres-
sion was begun on the day of liver replacement. This 
consisted of 5 daily doses of antithymocyte globulin 
(ATG, thymoglobulin®), a I-week course of medium-
dose prednisone that was tapered at the time of stem 
cell infusion, and conventional doses of sirolimus until 
liver function normalized. The strategy provided pre-
treatment for the second load of donor leukocytes on 
postoperative day 7. Neither the cells infused at day 7 
nor the recipient were subjected to much immunosup-
pression since the already minimal treatment was 
stopped a short time later. In their discussion, the au-
thors raised the possibility that the inability to eventu-
ally wean their third patient may have been due to their 
decision against early immunosuppression stoppage. 
Although they also drew attention to theoretical anti-
tolerogenic qualities of the tacrolimus that replaced 
sirolimus after 30 days, the best explanation may be 
that the unnecessary continuation of any potent T-ceU-
directed immunosuppressant can variably thwart the 
objective of eventual drug freedom. 
Figure IB shows what we believe to have been the role 
of the stem cell infUSion in the Belgium cases. In es-
sence. the recipients already were partially tolerized by 
the graft's passenger leukocytes at the time the cell 
infusion was given. Because the infused cells were a 
naIve population, they could have posed an increased 
risk of GVHD because circumstances had been created 
that potentially mimicked those in a parent to defense-
less offspring F1 hybrid rodent mode1.3s :l6 The added 
theoretical risk is depicted by the bulging inverted GVH 
response curve shown at the bottom of Figure lB. This 
threat was effectively defused in the Belgium cases by 
the nearly complete removal of mature T cells, as orig-
inally described in 1981 by Reisner et a1. 37 In an im-
portant thoughtful comment. the authors correctly 
pointed out that the second cell delivery might not have 
been essential, since the passenger leukocytes of the 
graft could have been all that was necessary to achieve 
tolerance (Fig. lA). 
What. then. was the Single-most important element of 
their protocol? With or without a cell infusion, the crit-
ical step in the induction of tolerance probably was the 
minimum use of posttransplant immunosuppression. 
If just enough treatment is given at precisely the right 
time and then stopped, tolerogenesis is "permitted." 
This was described in 1992 as " ... responses of coex-
isting donor and reCipient cells, each to the other, re-
sulting in reciprocal clonal exhaustion. followed by pe-
ripheral clonal deletion,'·14.1s Assessment of the 
completeness and durability of the tolerance may re-
quire follow-ups of 2 or more years since the effects of 
conditioning with a potent lymphoid depleting antibody 
are long-lasting. Nevertheless. the observations in the 3 
cases described by Donckier et a1. add to the consider-
able historical evidence15.34.38-42 that drug-free toler-
ance in a significant number of HLA-mismatched liver 
transplant reCipients is a realizable objective. 
There are several summary caveats: (1) Although he-
matolymphopoietic chimerism will be a prerequisite, 
sustained macrochimerism may be disadvantageous to 
the host. arid it is more apt to be a complication (e.g .. 
GVHD) than the desired objective of tolerance; (2) the 
ability of micro chimerism to perpetuate alloengraft-
ment under no (or low) immunosuppression will de-
pend on the efficiency of the exhaustion-deletion 
achieved at the outset; (3) heavy immunosuppression 
with agents that block T-cell activation must be used 
sparingly after arrival of donor antigen, because T-cell 
activation is a prerequisite for donor-speCific T-cell de-
letion; (4) permanent deletion or suppression of all do-
nor specific T cells is simply unrealistic; (5) rather than 
being a state of absolute immune quiescence, tolerance 
is a low-grade active process (with or without the aid of 
maintenance immunosuppression) that depends on 
finding a stable dynamiC balance favoring mobile donor 
antigen over donor-specific CTL; (6) stability of this bal-
ance in organ recipients with microchimerism requires 
avoidance of the destruction of the minority population 
by mechanisms of immune ignorance that are not yet 
fully understood; and (7) chimerism-dependent or chi-
merism-independent adjunctive tolerance mechanisms 
other than immune ignorance may be contributory but 
they are not essential. 
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